Physician profile
Cora Oneal
NPI 1033712716
$6,311.46
in general payments reported to CMS, 2019-2025
39 companies · $675 in 2025
The $675 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,275 · 2022: $1,293 · 2023: $1,534 · 2024: $1,534 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,743.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.25 | 2021-2025 | |
| Novo Nordisk INC | $737.55 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $655.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $441.74 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Eisai INC. | $372.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.17 | 2022-2025 | |
| Ardelyx, INC. | $257.34 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $247.51 | 2021-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $241.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $237.37 | 2021-2024 | Arexvy, Shingrix |
| Astellas Pharma US INC | $234.56 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.20 | 2021-2024 | Jardiance |
| Pfizer INC. | $154.60 | 2021-2025 | |
| Daiichi Sankyo INC. | $149.28 | 2023-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $139.67 | 2023-2025 | Rexulti |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cora Oneal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.